StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Outlook Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$55.53M. For fiscal 2025 it was -$66.94M. The highest annual figure on record is -$26.59M in fiscal 2018.

Annual ebitda

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$66.94M–
FY2024Sep 30, 2024-$71.59M–
FY2023Sep 30, 2023-$53.08M–
FY2022Sep 30, 2022-$62.87M–
FY2021Sep 30, 2021-$51.46M–
FY2020Sep 30, 2020-$36.29M–
FY2019Sep 30, 2019-$32.94M–
FY2018Sep 30, 2018-$26.59M–
FY2017Sep 30, 2017-$33.19M–
FY2016Sep 30, 2016-$48.95M–
FY2015Sep 30, 2015-$44.74M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$10.80M–
Q2 FY2026CQ1 2026Mar 31, 2026-$14.00M–
Q1 FY2026CQ4 2025Dec 31, 2025-$13.45M–
Q4 FY2025CQ3 2025Sep 30, 2025-$17.28M–
Q3 FY2025CQ2 2025Jun 30, 2025-$15.72M–
Q2 FY2025CQ1 2025Mar 31, 2025-$12.36M–
Q1 FY2025CQ4 2024Dec 31, 2024-$21.58M–
Q4 FY2024CQ3 2024Sep 30, 2024-$22.85M–
Q3 FY2024CQ2 2024Jun 30, 2024-$19.53M–
Q2 FY2024CQ1 2024Mar 31, 2024-$18.91M–
Q1 FY2024CQ4 2023Dec 31, 2023-$10.29M–
Q4 FY2023CQ3 2023Sep 30, 2023-$12.45M–
Q3 FY2023CQ2 2023Jun 30, 2023-$18.13M–
Q2 FY2023CQ1 2023Mar 31, 2023-$6.83M–
Q1 FY2023CQ4 2022Dec 31, 2022-$15.68M–
Q4 FY2022CQ3 2022Sep 30, 2022-$13.94M–
Q1 FY2022CQ4 2021Dec 31, 2021-$13.10M–
Q4 FY2021CQ3 2021Sep 30, 2021-$13.38M–
Q1 FY2021CQ4 2020Dec 31, 2020-$14.11M–
Q4 FY2020CQ3 2020Sep 30, 2020-$9.93M–
Q3 FY2020CQ2 2020Jun 30, 2020-$11.83M–
Q2 FY2020CQ1 2020Mar 31, 2020-$6.70M–
Q1 FY2020CQ4 2019Dec 31, 2019-$8.01M–
Q4 FY2019CQ3 2019Sep 30, 2019-$11.80M–
Q3 FY2019CQ2 2019Jun 30, 2019-$4.81M–
Q2 FY2019CQ1 2019Mar 31, 2019-$6.89M–
Q1 FY2019CQ4 2018Dec 31, 2018-$9.43M–
Q4 FY2018CQ3 2018Sep 30, 2018-$11.59M–
Q3 FY2018CQ2 2018Jun 30, 2018-$6.40M–
Q2 FY2018CQ1 2018Mar 31, 2018-$6.12M–
Q1 FY2018CQ4 2017Dec 31, 2017-$2.50M–
Q4 FY2017CQ3 2017Sep 30, 2017-$2.24M–
Q3 FY2017CQ2 2017Jun 30, 2017-$6.66M–
Q2 FY2017CQ1 2017Mar 31, 2017-$7.16M–
Q1 FY2017CQ4 2016Dec 31, 2016-$17.13M–
Q4 FY2016CQ3 2016Sep 30, 2016-$9.35M–
Q3 FY2016CQ2 2016Jun 30, 2016-$21.43M–
Q2 FY2016CQ1 2016Mar 31, 2016-$2.36M–

More Outlook Therapeutics figures

See a number that looks wrong?